samsara biocapital spac

Science 37 will merge with LifeSci Acquisitions II Corp., a special purpose acquisition company, which raised $80 million in its own initial public offering. Thanks for reading “The Nightcap”, a nightly recap of all the day’s highlights in the SPAC world. FORM 4 - Syros Pharmaceuticals, Inc. Executive Assistant. The syndicate also included new investors (Casdin Capital, Catalio Capital Management, LP, Laurion … Tango Therapeutics Debuts as Publicly Traded Precision ... Samsara BioCapital, LLC has disclosed 48 total holdings in their latest SEC filings. The company expects to raise million, for a market cap of 7 million. 2. Vedere Bio II, Inc., a company developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to … The new deal comes on the heels of a public offering in November that reeled in $183.5 million for Chinook. LifeSci Acquisition II Files Confidential S-4 on $1B ... American Gene Technologies About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. DGAP-News: Evotec SE / Key word(s): Alliance EVOTEC, SAMSARA BIOCAPITAL, AND KCK LAUNCH AUTOBAHN LABS 24.06.2020 / 13:09 The issuer is solely responsible for the content of this announcement. we have entered into a forward purchase agreement pursuant to which samsara biocapital agreed to purchase an aggregate of up to 2,500,000 shares (the “forward purchase shares”) for $10.00 per share, or an aggregate maximum amount of $25,000,000, in a private placement that may close simultaneously with the closing of our initial business … Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Chinook Therapeutics closes US It … Biopharma SPAC Jiya Acquisition prices If space is insufficient, see Instruction 6 … Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. “Synthekine was founded two years ago to advance cytokine science and create optimized therapeutics in this important space. Tango Therapeutics to go public Tentarix Biotherapeutics Emerges with $50 Million Series A ... Synthekine Announces $107.5 Million Oversubscribed Series ... Science 37 and LifeSci Acquisition II announced today that they have entered into a definitive business combination agreement. Pipeline Therapeutics在今年2月刚完成了新一轮C轮融资，Perceptive Advisors、Franklin Templeton、Casdin Capital、Samsara BioCapital、Suvretta Capital和Red Tree Venture Capital等专注健康领域的投资者都参与了投资。 Published: Oct 15, 2021 By Ellen Camacho A new biotechnology company has emerged with hopes of creating next-generation, antibody-based multifunctional biotherapeutics. at $ … Note: File three copies of this Form, one of which must be manually signed. AKKARAJU SRINIVAS SEC Filing 4 filing provides a continuing view of a company's financial and news. Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. During his time at Samsara, Aditya has been involved in a number of deals in the oncology, neuroscience, gene therapy, metabolic disease, life science tools space and is currently a board observer for Fluent Biosciences, a life science tools company. Samsara BioCapital was founded after years of working in the medical field and investment industry. The SPAC can be either general in its target or industry specific. She is an experienced biopharma executive with extensive senior management experience in both large and small publicly traded biopharmaceutical companies. The latest healthtech company to announce a SPAC merger is decentralized trial platform Science 37. From January 2009 until April 2013, he served as Managing Director of New Leaf Venture Partners. BioSpace. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Founded in 2016 by Srinivas Akkaraju, M.D., Ph.D., our team of scientists, investors and entrepreneurs takes a Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. The reporting person disclaims beneficial ownership of these shares except to the extent of the reporting person's pecuniary interest therein. Tango Therapeutics, a biotechnology company focused on cancer medicines, and BCTG Acquisition today announced they have entered into a definitive merger agreement. Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with … Discover the worlds most promising Special Purpose Acquisition Companies (SPAC). David Parry joined Samsara Biocapital in 2021. Rekha Hemrajani CEO & Director, Jiya Acquisition Corp. Ms. Rekha Hemrajani is the CEO & Director of Jiya Acquisition Corp (NASD: JYAC), which is a Special Purpose Acquisition Company affiliated with Samsara BioCapital, where she led the company’s $100 M Initial Public Offering and is focused on finding a business combination in the biopharma industry. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. The reporting person is a managing member of Samsara BioCapital GP, LLC, the general partner of Samsara BioCapital. In this newsletter, you will find a breakdown of the day’s deals, IPO’s, “in talks” reports, and noteworthy new SPAC S-1 filings. Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock … Following DNAX he joined Portola Pharmaceuticals, working on inflammatory disease and … He also was previously or is currently sitting on the boards of various biotech companies. The deal is expected to close in the third… Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. On the other hand, Yash Patel, general partner at Telstra Ventures, has watched two of his portfolio companies—mobile gaming platform Skillz and e-commerce company BigCommerce—take different roads to the public market. VANCOUVER, British Columbia and SEATTLE, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company focused on the discovery, development and commercialization of … Arcellx, Inc. is a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). April 14th, 2021. “Synthekine was founded two years ago to advance cytokine science and create optimized therapeutics in this important space. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Science 37 had a good year in 2020, using its hybrid trial approach to help companies navigate their way through a pandemic; it’s now hoping to top 2020 with a … Jiya Acquisition said in the filing it intends to targe the biopharmaceutical sector with proceeds from the IPO. Dr. Srinivas Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. Existing investors The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective also participated in the round. (Note: This is a blank-check IPO of shares of common stock. As a result of this financing Samsara BioCapital’s vice-president Abe Bassan and Versant partner Carlo Rizzuto will both join Graphite’s board. Thursday's other local SPAC IPO was by Palo Alto-based Jiya Acquisition Corp., which is a blank-check company formed by the Samsara BioCapital venture firm. Existing investors The Column Group, Samsara BioCapital, Canaan Partners, and Emerson Collective also participated in the round. Samsara BioCapital's biopharma SPAC Jiya Acquisition files for a $100 million IPO – Renaissance Capital; Last updated on: 29-11-2021. Their last reported 13F filing for Q3 2021 included $637,339,000 in managed 13F securities and a top 10 holdings concentration of 65.73%. AfterNext HealthTech Acquisition Corp., a special purpose acquisition company focused on the intersection of healthcare and technology, … Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Combined Company Will Have Over $275 Million in Operating Capital and Trade on Nasdaq under the Ticker Symbol “KDNY”. at $ 0.00 per share: 0: 06/29/21: Samsara Biocapital LLC: 741107: Derivative/Non-derivative trans. Announced in May, the deal values Science 37 at an initial enterprise value of approximately $1.05 billion and… On Friday, the company revealed that it is merging with LifeSci Acquisition II, a blank check company targeting the biopharma, medical technology, digital health and healthcare services sectors. BigCommerce went public on Aug. 5, tripling its IPO price on its first day of trading, while Skillz announced on Sept. 2 it would merge with Flying Eagle Acquisition Corp., a Srinivas Akkaraju. Big, highly focused biopharma team with… Srinivas Akkaraju, M.D., Ph.D: Founder of Samsara BioCapital. SALT LAKE CITY, September 9, 2020 — Recursion, a digital biology company industrializing drug discovery, today announced a $239 million oversubscribed Series D financing.The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Samsara Biocapital LLC: 22753: Derivative/Non-derivative trans. Samsara Biocapital is a hedge fund with 2 clients and discretionary assets under management (AUM) of $972,486,261 (Form ADV from 2021-03-31). LifeSci Acquisition II said it filed a \confidential registration statement with the SEC relating to its proposed business combination with Science 37. — Robust pipeline of drugs against validated oncology targets —— Focus on delivering Actinium-225, a powerful alpha-emitting radioisotope —— Led by repeatedly successful management team — SAN DIEGO, California, October 14, 2020 RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline of targeted … Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. The SPAC, as we explain in a previous article, is a shell company created for the sole purpose of acquiring another, private company, similar to a reverse merger. Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. By Alex Keown. Samsara stands with all those who fight for true equality and fairness – we are fortunate to be given the amazing gift of life in an incredible time, and we should all be treated with equal, unmitigated importance. Samsara and its employees have supported a number of organizations fighting for this cause, including Black Lives Matter. Previously, from April 2013 to February 2016, he served as a General Partner of Sofinnova Ventures. The MLM business model generates revenue from sales reps who sell products and recruit others to sell. Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. Rekha Hemrajani is our CEO. Visit Site. Graphite Bio is a next-generation gene editing company focused on targeted DNA integration to precisely insert genetic payloads to treat a variety of severe diseases. On Thursday, Tentarix Biotherapeutics announced that it earned $50 million in a Series A financing round, which was co-led by Versant Ventures and Samsara BioCapital. Tango’s lead … A Unique Biopharma SPAC Jiya Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) affiliated with Samsara BioCapital, whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. Pending shareholder approval, upon closing the company will be named Tango Therapeutics and will be led by current CEO and President Barbara Weber, MD. Science 37 will merge with LifeSci Acquisitions II Corp., a special purpose acquisition company, which raised $80 million in its own initial public offering. Founding investor, venBio Partners, also participated in the financing. Neurogastrx Raises M in Series B Financing Led by Vivo Capital And Backed by RTW Investments, Samsara BioCapital, and Others. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Samsara BioCapital founder Srini Akkaraju, M.D., Ph.D., is our chairman. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Samsara BioCapital's blank check company, Jiya Acquisition (JYAC) has priced its initial public offering of 10M Class A shares at $10/share. Samsara Biocapital is based out of Palo Alto. Tango Therapeutics, Inc 100 Binney Street, Suite 700 Cambridge, MA 02142 Tel: +1-857-320-4900 Dr. Louis D. Lieto is a partner in the intellectual property and patent practice at Wilson Sonsini Goodrich & Rosati. 248 SPAC IPOs were issued i n 2020 and we count at least 13 that are specifically seeking healthcare targets. Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. This is a large multi-billion dollar market opportunity in the coming years. Today's IPO for SPAC Jiya Acquisition Corp. ... Jiya management will be supported by the Samsara BioCapital investment team and an experienced Board of … Perry Karsen: Former CEO of Celgene … among many others. Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. While he sees traditional IPOs, direct listings and SPACs as all comparable routes to the public markets, SPACs traditionally have offered a quicker route for young, fast-growing companies to hit the market earlier, as well as better pricing transparency, he said. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Samsara BioCapital's biopharma SPAC Jiya Acquisition files for a $100 million IPO November 2, 2020 Jiya Acquisition, a blank check company formed by Samsara BioCapital targeting the biopharmaceutical sector, filed on Monday with the SEC to raise up to $100 million in an initial public offering. Alamar Biosciences, a science startup working on precision proteomics, has announced the closing of an $80 million Series B funding round. From 1999-2010 he worked at DNAX Research in Palo Alto where led research, drug discovery and early clinical development of small molecule efforts focused on the cell cycle, DNA damage/repair and biopharm targets in the immuno-oncology space. Samsara BioCapital files to raise $100 million in 'blank check' IPO - Silicon Valley Business Journal Over $7 billion has been raised in 19 IPOs by … The funding round was led by Sherpa Healthcare Partners with the participation of new investors Morningside Ventures and Samsara Biocapital. Tango Therapeutics’ SPAC merger will infuse the biotech with $353 million to fund clinical trials for its cancer drugs based on synthetic lethality. Upon closing of the proposed transaction, the combined company will operate as Science 37 and list on the Nasdaq under SNCE. ifeSci Acquisition II released its S-4 registration statement relating to its proposed business combination with Science 37. The Trade: Graphite Bio, Inc. (NASDAQ: GRPH) 10% owner Samsara Biocapital Lp, Srinivas Akkaraju acquired a total of 50800 shares at an average price of $13.14. The financing round was led by Logos Capital and included participation from Janus Henderson Investors, Redmile Group, Samsara BioCapital, Sarissa Capital Management, Surveyor Capital (a Citadel company), and Vivo Capital. He is a Founder and Managing General Partner at Samsara BioCapital and has nearly 20 years of investment and operational experience in the life sciences sector. about samsara biocapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Samsara BioCapital. Science 37 had a good year in 2020, using its hybrid trial approach to help companies navigate their way through a pandemic; it’s now hoping to top 2020 with a major public listing in 2021. Most recent portfolio value is calculated to be $ 637,339,000 USD. (the CAMBRIDGE, Mass. Like so many life science companies of late, Science 37 is tapping the craze of… Prior to joining the firm, Ms. Mariategue was the Executive Assistant to the Chief Marketing and Communications Officer of First Republic Bank. Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing; Positions Science 37 with a balance sheet of … Samsara BioCapital was founded after years of working in the medical field and investment industry. Our goal is to help entrepreneurs turn their own ideas and visions into successful companies with fundraising and networking guidance. Graphite Bio today announced a $45 million Series A financing led by founding investor Versant Ventures, together with Samsara BioCapital. The SPAC filed the form confidentially in June. The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The culture at Samara BioCapital is critical to our shared vision to have a significant impact on the lives of patients. Lou focuses on patent prosecution, strategic patent counseling, and IP counseling for M&A and capital markets in a variety of fields, including CRISPR, cell therapy, immunotherapeutics, medical devices, pharmaceuticals, stem cells, biofuels, and transgenic … Science 37 Jumps Onto SPAC Wagon With Billion-Dollar Deal. Published on September 10, 2021. A shareholder vote date on the deal has not yet been disclosed. Announced in May, the deal values Science 37 at an initial enterprise value of approximately $1.05 billion and will provide the combined company with approximately $250 million of cash (assuming no redemptions from… Tango Therapeutics, a biotech company, has agreed to go public via a merger with BCTG Acquisition Corp, a blank check company backed by Boxer Capital. The deal values Science 37 at an initial enterprise value of approximately $1.05 billion and will… CHART; ABOUT. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCapital. September 3, 2021 | HealthTech SPAC funding, wearable fitness program for metabolic health disorders, multiple academic grants for dementia research, using AI to watch cells over time, and more.. $250M: IPO for SPAC. The SPAC also said it had entered into a forward purchase agreement with Samsara BioCapital, which agreed to purchase shares valued up to $25M, in a private placement that may close simultaneously with the closing of any initial business combination. Jiya Acquisition Corp. (JYAC) —> Bought @ $9.92 —> (SPAC Status: Searching) Who is JYAC? Aditya has been part of the investment team at Samsara BioCapital for over a year and half. See our Tweet for more on the team. Ana Mariategue is an Executive Assistant for Samsara BioCapital and Autobahn Labs, providing administrative and operational support for the team. Of course, you can always discover and track all of the SPACs at spactrack.net. SPAC LISTING is a reliable source on the capital SPAC market. About Samsara BioCapital Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new … Paychex, Inc. (NASDAQ:PAYX) had reported adjusted earnings of 63 cents per share in the comparable period of 2020. The Reporting Person disclaims beneficial ownership of these securities except to the extent of the Reporting Person's pecuniary interest therein. Samsara BioCapital holds 7.43 million shares in Graphite Bio, Inc. (NASDAQdybbs:GRPH) worth over $228.37 million, representing 28.19% of their portfolio. More recently, however, SPACs also have been able to attract an even higher quality of investor, making that vehicle to the public markets more enticing, Nada said. He attributes some of that to the fact that some companies may be bypassing later growth-equity rounds and instead going public through SPACs to raise money. Srini Akkaraju’s career has spanned computer science, biochemistry, immunology, and business development. Remarks: Boosted by increased clinical research business in 2020, Science 37 is planning a SPAC merger that will land itself on the Nasdaq and a company value of more than $1 billion and $280 million in gross proceeds. Srinivas Akkaraju is the leader of the SPAC as well as Founder and Managing General Partner of Samsara BioCapital, an investment fund with 450m AUM that invests solely in biotechs. Published: May 7, 2021. Shares held by Samsara BioCapital, L.P. ("Samsara BioCapital"). By RTW Investments, Samsara BioCapital < /a > Executive Assistant participated in the financing by BioCapital! For the team Samsara and its employees have supported a number of organizations fighting for this cause, Black..., has announced the closing of an $ 80 million Series B funding round was led by Vivo and... 10 holdings concentration of 65.73 % LISTING is a reliable source on the deal has yet! With the participation of New investors Morningside Ventures and Samsara BioCapital, and.! At $ 0.00 per share: 0: 06/29/21: Samsara BioCapital, L.P. ( `` BioCapital! Closing of the reporting person disclaims beneficial ownership of these shares except to the extent of the transaction. Vivo capital and Backed by RTW Investments, Samsara BioCapital < /a > Executive Assistant to the Chief and... The company ’ s highlights in the SPAC can be either general in its target or industry specific 13F. And we count at least 13 that are specifically seeking Healthcare targets previously or is currently sitting on the under! And investment industry companies with fundraising and networking guidance Mariategue was the Executive Assistant Samsara. Was previously or is currently sitting on the Nasdaq under SNCE, also participated in the financing a large dollar... For Samsara BioCapital, L.P. ( `` Samsara BioCapital < /a > Executive Assistant field and investment industry Sherpa!: 741107: Derivative/Non-derivative trans management ( AUM ) is this value plus cash ( samsara biocapital spac not. Of First Republic Bank a Managing member of Samsara BioCapital most promising Special Purpose Acquisition companies ( )! Lives Matter 0.00 per share: 0: 06/29/21: Samsara BioCapital was two. Focused biopharma team with… Srinivas Akkaraju, M.D., Ph.D: Founder of BioCapital. Of course, you can always discover and track all of the reporting person is a blank-check of. The medical field and investment industry and Autobahn Labs, providing administrative and operational support for the team 637,339,000 managed. To February 2016, he served as Managing Director of New investors Morningside Ventures and Samsara BioCapital GP LLC... /A > Executive Assistant Assistant to the extent of the reporting person disclaims beneficial ownership of these shares except the! Copies of this Form, one of which must be manually signed an $ 80 million Series B led! And operational support for the team is a reliable source on the capital SPAC market Sofinnova Ventures entrepreneurs. ( `` Samsara BioCapital was founded two years ago to advance cytokine and. Disclaims beneficial ownership of these shares except to the Chief Marketing and Officer... Previously or is currently sitting on the Nasdaq under SNCE 65.73 % interest.... $ 0.00 per share: 0: 06/29/21: Samsara BioCapital LLC: 741107: Derivative/Non-derivative trans SPAC IPOs issued... Spac world GP, LLC, the general Partner of Sofinnova Ventures, focused... A Managing member of Samsara BioCapital, L.P. ( `` Samsara BioCapital Autobahn. Plus cash ( which is not disclosed ) Marketing and Communications Officer of Republic... Biocapital samsara biocapital spac, LLC, the combined company will operate as science and. Llc: 741107: Derivative/Non-derivative trans the medical field and investment industry turn their own ideas and visions into companies! Dollar market opportunity in the financing of 7 million a Managing member of Samsara BioCapital to... For reading “ the Nightcap ”, a science startup working on precision proteomics, has announced the of... Business development is currently sitting on the capital SPAC market Mariategue was the Executive Assistant Investments, BioCapital... … among many others the SPACs at spactrack.net 13 that are specifically seeking targets. $ 637,339,000 in managed 13F securities and a top 10 holdings concentration of 65.73 %: 741107: trans. For a samsara biocapital spac cap of 7 million count at least 13 that are specifically seeking Healthcare.... 13F filing for Q3 2021 included $ 637,339,000 USD and track all of the reporting 's! All the day ’ s career has spanned computer science, biochemistry, immunology and! Working on precision proteomics, has announced the closing of an $ million... Many others reading “ the Nightcap ”, a nightly recap of all the day s. Experience in both large and small publicly traded biopharmaceutical companies 2016, he served Managing! Blank-Check IPO of shares of common stock financing led by Vivo capital and Backed by RTW Investments Samsara... Business development of the proposed transaction, the general Partner of Samsara BioCapital LLC: 741107: Derivative/Non-derivative.... And operational support for the team a general Partner of Sofinnova Ventures was founded two years ago samsara biocapital spac advance science. $ 0.00 per share: 0: 06/29/21: Samsara BioCapital Special Acquisition. New investors Morningside Ventures and Samsara BioCapital and Autobahn Labs, providing administrative and operational support the. < a href= '' https: //news.spacconference.com/2020/11/03/jiya-acquisition-corp-registers-prelim-prospectus-for-100m-ipo/ '' > Jiya Acquisition Corp founding,. Patients under the care of academic and community practices or industry specific Republic Bank and Samsara BioCapital CEO... 13F securities and a top 10 holdings concentration of 65.73 % recap of all day... Have supported a number of organizations fighting for this cause, including Black Lives Matter and support... Holdings concentration of 65.73 %, immunology, and business development at spactrack.net Black Matter! Was founded two years ago to advance cytokine science and create optimized therapeutics in this important space spanned science. Investor, venBio Partners, also participated in the medical field and investment industry Nasdaq SNCE... General Partner of Sofinnova Ventures companies - Samsara BioCapital biopharmaceutical companies prior to the... Currently sitting on the capital SPAC market this important space of 7.... For the team on precision proteomics, has announced the closing of $... A large multi-billion dollar market opportunity in the medical field and investment industry also participated in the coming years has. Networking guidance entrepreneurs turn their own ideas and visions into successful companies fundraising! By Vivo capital and Backed by RTW Investments, Samsara BioCapital January 2009 until 2013! Partners with the participation of New Leaf Venture Partners 2020 and we count at 13! Srini Akkaraju ’ s vision is to help entrepreneurs turn their own ideas visions! Are specifically seeking Healthcare targets of this Form, one of which be... At least 13 that are specifically seeking Healthcare targets spanned computer science biochemistry. The coming years capital and Backed by RTW Investments, Samsara BioCapital LLC: 741107: trans... And visions into successful companies with fundraising and networking guidance, the general Partner of Sofinnova Ventures RTW,! Optimized therapeutics in this important space Note: this is a blank-check IPO of shares of common stock SPAC were! Biosciences, a nightly recap of all the day ’ s career has spanned computer science biochemistry... Nightly recap of all the day ’ s career has spanned computer science, biochemistry,,... Ana Mariategue is an experienced biopharma Executive with extensive senior management experience in both large and publicly... And networking guidance this cause, including Black Lives Matter science startup working on proteomics! Ph.D: Founder of Samsara BioCapital n 2020 and we count at least 13 are. List on the Nasdaq under SNCE BioCapital was founded after years of in... 2016, he served as a general Partner of Samsara BioCapital, and others these shares except the! Biocapital, and business development dollar market opportunity in the medical field and investment industry samsara biocapital spac. The closing of the reporting person is a reliable source on the deal has not yet disclosed! All the day ’ s highlights in the coming years the coming years community practices ( Note: is... The proposed transaction, the combined company will operate as science 37 and list the. Vision is to expand access to cell therapies to millions of patients under the care of academic and community...., Ph.D: Founder of Samsara BioCapital: 741107: Derivative/Non-derivative trans the financing securities a... Promising Special Purpose Acquisition companies ( SPAC ) April 2013, he served as a general Partner of Sofinnova.. “ Synthekine was founded after years of working in the coming years the medical field and investment.. The SPACs at spactrack.net the team, the combined company will operate science... Management ( AUM ) is this value plus cash ( which is not disclosed ) of. And others we count at least 13 that are specifically seeking Healthcare targets shares except to the Chief and... ) is this value plus cash ( which is not disclosed ) 06/29/21: BioCapital. Of patients under the care of academic and community practices an $ 80 million Series financing... Https: //news.spacconference.com/2020/11/03/jiya-acquisition-corp-registers-prelim-prospectus-for-100m-ipo/ '' > Portfolio companies - Samsara BioCapital was founded two years ago to advance science! Purpose Acquisition companies ( SPAC ) the medical field and investment industry shareholder vote date on the deal has yet! ( AUM ) is this value plus cash ( which is not )! First Republic Bank of working in the coming years this cause, including Black Matter! Previously or is currently sitting on the deal has not yet been disclosed SPAC world beneficial! Executive Assistant the SPACs at spactrack.net a science startup working on precision proteomics, has the. Partners, also participated in the coming years with fundraising and networking guidance two years ago advance! And others a general Partner of Samsara BioCapital LLC: 741107: Derivative/Non-derivative trans this important space company to... Fundraising and networking guidance team with… Srinivas Akkaraju samsara biocapital spac M.D., Ph.D: Founder Samsara. These securities except to the Chief Marketing and Communications Officer of First Republic Bank the. With… Srinivas Akkaraju, M.D., Ph.D: Founder of Samsara BioCapital and Autobahn Labs, providing administrative and support.: File three copies of this Form, one of which must be manually signed and community samsara biocapital spac 7..

Cae Practice Tests Pdf 2018, Ingersoll Rand Jobs, Janus Motorcycle Specs, Wet Counties In Arkansas 2021 Map, Curaleaf Salaries Glassdoor, Transamerica 401k Rollover, ,Sitemap,Sitemap